The gene therapy market is projected to grow at an annualized rate of 30%, {till 2030}
Roots
Analysis
has done a detailed study on Gene Therapy Market (4th Edition), 2020-2030, covering key
aspects of the industry’s evolution and identifying potential future growth
opportunities.
To order this 720+
page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Key Market Insights
§
The gene therapy market is characterized by a healthy drug
pipeline, with 10 approved molecules and over 820 product candidates being
evaluated for the treatment of multiple disease indications, worldwide
§
Most of the contemporary therapeutic leads are currently in
the early stages of clinical development; a variety of viral and non-viral
vectors are being used across different therapeutic approaches for gene
therapies
§
Around 400 gene therapy focused clinical trials have been
registered across the globe; most of these trials are evaluating the therapies
for the treatment of oncological indications
§
In order to tap into the lucrative opportunity offered by
gene therapies, big pharma players have adopted various approaches, from
proprietary product development to strategic investments
§
Several patents related to gene
therapies and affiliated technologies have been filed / granted; the value of
this intellectual capital is being realized through both licensing agreements
and marketing exclusivity
§
In the recent past, a considerable increase in the M&A
activity has been observed among industry stakeholders; this trend can be
attributed to the ongoing capability / portfolio consolidation efforts of
involved players
§
Foreseeing a lucrative return, many
public and private investors have made investments worth over USD 25 billion,
across more than 350 instances, in the period between 2015 and 2020
§
Case Study: CMOs offering vector manufacturing services have become an
integral part of the gene therapy supply chain, owing to their ability to
overcome the associated challenges
§
Treatment cost is one of the major concerns in this market;
we anticipate more affordable pricing and reimbursement strategies to evolve in
due course
§
Prevalent trends indicate that the demand for gene
therapies is poised to grow significantly as more late-stage therapies get
commercialized in the short team using different vectors and type of therapies
§
The projected future opportunity is expected to be
distributed across different therapeutic areas, types of therapies, types of
therapeutic approaches, routes of administrations and key geographical regions
§
To monetize the full potential, stakeholders are already
actively exploring diverse commercialization strategies, across different
stages of a product’s launch cycle
For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter
Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Evolution
of Gene Therapies
3.3. Classification
of Gene Therapies
3.3.1. Somatic and
Germline Therapies
3.3.2. Ex Vivo and
In Vivo Therapies
3.4. Routes of
Administration
3.5. Mechanism
of Action of Gene Therapies
3.6. Overview of
the Basic Concepts of Gene Editing
3.6.1. Evolution of
Genome Editing
3.6.2. Applications
of Genome Editing
3.6.3. Genome
Editing Techniques
3.7. Advantages
and Disadvantages of Gene Therapies
3.8. Ethical and
Social Concerns Related to Gene Therapies
3.9. Constraints
and Challenges Related to Gene Therapies
3.9.1. Therapy
Development Concerns
3.9.2. Manufacturing
Concerns
3.9.3. Commercial
Viability Concerns
4. GENE
DELIVERY VECTORS
4.1. Chapter Overview
4.2. Viral and
Non-Viral Methods of Gene Transfer
4.3. Viral
Vectors for Genetically Modified Therapies
4.4. Types of
Viral Vectors
4.4.1. Adeno-associated
Viral Vectors
4.4.1.1. Overview
4.4.1.2. Design and
Manufacturing
4.4.1.3. Advantages
4.4.1.4. Limitations
4.4.2. Adenoviral
Vectors
4.4.2.1. Overview
4.4.2.2. Design and
Manufacturing
4.4.2.3. Advantages
4.4.2.4. Limitations
4.4.3. Lentiviral
Vectors
4.4.3.1. Overview
4.4.3.2. Design and
Manufacturing
4.4.3.3. Advantages
4.4.3.4. Limitations
4.4.4. Retroviral
Vectors
4.4.4.1. Overview
4.4.4.2. Design and
Manufacturing
4.4.4.3. Advantages
4.4.4.4. Limitations
4.4.5. Other Viral
Vectors
4.4.5.1. Alphavirus
4.4.5.2. Foamy Virus
4.4.5.3. Herpes
Simplex Virus
4.4.5.4. Sendai Virus
4.4.5.5. Simian Virus
4.4.5.6. Vaccinia
Virus
4.5. Types of
Non-Viral Vectors
4.5.1. Plasmid DNA
4.5.2. Liposomes,
Lipoplexes and Polyplexes
4.5.3. Oligonucleotides
4.5.4. Other
Non-Viral Vectors
4.5.5. Gene
Delivery Using Non-Viral Vectors
4.5.5.1. Biolistic
Methods
4.5.5.2. Electroporation
4.5.5.3. Receptor
Mediated Gene Delivery
4.5.5.4. Gene
Activated Matrix (GAM)
5. REGULATORY
LANDSCAPE AND REIMBURSEMENT SCENARIO
5.1. Chapter Overview
5.2. Regulatory
Guidelines in North America
5.2.1. The US
Scenario
5.2.2. Canadian
Scenario
5.3. Regulatory
Guidelines in Europe
5.4. Regulatory
Guidelines in Asia-Pacific
5.4.1. Chinese
Scenario
5.4.2. Japanese Scenario
5.4.3. South Korean
Scenario
5.4.4. Australian
Scenario
5.4.5. Hong Kong
Scenario
5.5. Reimbursement
Scenario
5.5.1. Challenges
Related to Reimbursement
5.6. Commonly
Offered Payment Models for Gene Therapies
6. MARKET OVERVIEW
6.1. Chapter Overview
6.1.1. Analysis by
Phase of Development of Gene Therapy
6.2. Gene
Therapy Market: Clinical and Commercial Pipeline
6.2.1. Analysis by
Phase of Development
6.2.2. Analysis by
Therapeutic Area
6.2.3. Analysis by
Type of Vector Used
6.2.4. Analysis by
Type of Gene
6.2.5. Analysis by
Therapeutic Approach
6.2.6. Analysis by
Type of Gene Therapy
6.2.7. Analysis by
Route of Administration
6.3. Gene
Therapy Market: Early Stage Pipeline
6.3.1. Analysis by
Phase of Development
6.3.2. Analysis by
Therapeutic Area
6.3.3. Analysis by
Type of Vector Used
6.3.4. Analysis by
Type of Gene
6.3.5. Analysis by
Therapeutic Approach
6.3.6. Analysis by
Type of Gene Therapy
6.2.7. Analysis by
Route of Administration
6.4. Gene
Therapy Candidates: Special Designations
6.4.1. Analysis by
Special Designation(s) Awarded
6.5. Grid Representation: Analysis by Phase of
Development, Therapeutic Area and Therapeutic Approach
7. COMPETITIVE
LANDSCAPE
7.1. Chapter Overview
7.2. Gene
Therapy Market: List of Developers
7.2.1. Analysis by
Year of Establishment
7.2.2. Analysis by
Company Size
7.2.3. Analysis by
Geography
7.3. Key
Players: Analysis by Number of Product Candidates
8. MARKETED
GENE THERAPIES
8.1. Chapter Overview
8.2. Gendicine®
(Shenzhen Sibiono GeneTech)
8.2.1. Company
Overview
8.2.2. Development
Timeline
8.2.3. Mechanism of
Action and Vectors Used
8.2.4. Target
Indication(s)
8.2.5. Current
Status of Development
8.2.6. Manufacturing,
Dosage and Sales
8.3. Oncorine®
(Shanghai Sunway Biotech)
8.3.1. Company
Overview
8.3.2. Development
Timeline
8.3.3. Mechanism of
Action and Vectors Used
8.3.4. Target
Indication(s)
8.3.5. Current
Status of Development
8.3.6. Manufacturing,
Dosage and Sales
8.4. Rexin-G®
(Epeius Biotechnologies)
8.4.1. Company
Overview
8.4.2. Development
Timeline
8.4.3. Mechanism of
Action and Vector Used
8.4.4. Target
Indication(s)
8.4.5. Current
Status of Development
8.4.6. Manufacturing,
Dosage and Sales
8.5. Neovasculgen®
(Human Stem Cells Institute)
8.5.1. Company
Overview
8.5.2. Development
Timeline
8.5.3. Mechanism of
Action and Vectors Used
8.5.4. Target
Indication(s)
8.5.5. Current
Status of Development
8.5.6. Manufacturing,
Dosage and Sales
8.6. Imlygic®
(Amgen)
8.6.1. Company
Overview
8.6.2. Development
Timeline
8.6.3. Mechanism of
Action and Vectors Used
8.6.4. Target
Indication(s)
8.6.5. Current
Status of Development
8.6.6. Manufacturing,
Dosage and Sales
8.7. Strimvelis®
(Orchard Therapeutics)
8.7.1. Company
Overview
8.7.2. Development
Timeline
8.7.3. Mechanism of
Action and Vectors Used
8.7.4. Target
Indication(s)
8.7.5. Current
Status of Development
8.7.6. Manufacturing,
Dosage and Sales
8.8. Luxturna™
(Spark Therapeutics)
8.8.1. Company
Overview
8.8.2. Development
Timeline
8.8.3. Mechanism of
Action and Vector Used
8.8.4. Target
Indication(s)
8.8.5. Current
Status of Development
8.8.6. Manufacturing,
Dosage and Sales
8.9. Zolgensma™
(Novartis Gene Therapies)
8.9.1. Company
Overview
8.9.2. Development
Timeline
8.9.3. Mechanism of
Action and Vector Used
8.9.4. Target
Indication(s)
8.9.5. Current
Status of Development
8.9.6. Manufacturing,
Dosage and Sales
8.10. Collategene®
(AnGes)
8.10.1. Company
Overview
8.10.2. Development
Timeline
8.10.3. Mechanism of
Action and Vector Used
8.10.4. Target
Indication(s)
8.10.5. Current
Status of Development
8.10.6. Manufacturing,
Dosage and Sales
8.11. Zyntelgo™
(bluebird bio)
8.11.1. Company
Overview
8.11.2. Development
Timeline
8.11.3. Mechanism of
Action and Vector Used
8.11.4. Target
Indication(s)
8.11.5. Current
Status of Development
8.11.6. Manufacturing,
Dosage and Sales
9. KEY
COMMERCIALIZATION STRATEGIES
9.1. Chapter Overview
9.2. Successful
Drug Launch Strategy: ROOTS Framework
9.3. Successful
Drug Launch Strategy: Product Differentiation
9.4. Commonly
Adopted Commercialization Strategies based on Phase of Development of Product
9.5. List of
Currently Approved Gene Therapies
9.6. Key
Commercialization Strategies Adopted by Companies Focused on Gene Therapy
9.6.1. Strategies
Adopted Before Therapy Approval
9.6.2. Strategies
Adopted During / Post Therapy Approval
9.7. Concluding
Remarks
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Comments
Post a Comment